| Catalog No. | Size | Price (USD) |
| 10342-R102-1 | 1 mL | $1,969.87 |
| 10342-R102-20 | 20 µL | $118.49 |
| 10342-R102-50 | 50 µL | $177.58 |
| 10342-R102-100 | 100 µL | $340.51 |
General Information
| Product name | Recombinant Anti-interferon-alpha/IFNA5 Antibody, Rabbit Monoclonal |
| Validated applications | ELISA(Cap) (FAQ Protocol) |
| Species reactivity | Reacts with: Human |
| Specificity | Human interferon-alpha/IFNA5 |
| Immunogen | Recombinant Human IFNA5/IFNaG Protein (Catalog#10342-H08H) |
| Preparation | This antibody was obtained from a rabbit immunized with purified, recombinant Human IFNA5/IFNaG (rh IFNA5/IFNaG; Catalog#10342-H08H; P01569; Met1-Glu189). |
| Source | Monoclonal Rabbit IgG Clone #102 |
| Purification | Protein A |
| Formulation | 0.2 μm filtered solution in PBS |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Synonyms: Anti-IFN-alpha-5 Antibody; Anti-IFN-alphaG Antibody; Anti-INA5 Antibody; Anti-INFA5 Antibody; Anti-leIF G Antibody
Background Information
| Full Name | interferon, alpha 5 |
| Description | Interferon, alpha 5 (IFNA5) belongs to the alpha/beta interferon family. IFNA5 is the only IFNA subtype detected in normal liver, while a mixture of subtypes is observed in the liver tissue of patients with chronic hepatitis C. Interferons are produced by macrophages, IFN-alpha has antiviral activities. Interferon stimulates the production of two enzymes: a protein kinase and an oligoadenylate synthetase. IFN-alpha, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of growth and differentiation, affecting cellular communication and signal transduction pathways as well as immunological control. Originally discovered as an antiviral substance, the efficacy of IFN-alpha in malignant, viral, immunological, angiogenic, inflammatory, and fibrotic diseases suggests a spectrum of interrelated pathophysiologies. IFN-alpha emerged as a prototypic tumor suppressor protein that represses the clinical tumorigenic phenotype in some malignancies capable of differentiation. |
| References |
|
